Zomedica (NYSEAMERICAN:ZOM) Announces Quarterly Earnings Results

Zomedica (NYSEAMERICAN:ZOM – Get Rating) released its quarterly earnings data on Wednesday. The company reported ($0.01) earnings per share for the quarter, Yahoo Finance reports. Zomedica had a negative net margin of 90.74% and a negative return on equity of 6.35%. The firm had revenue of $6.16 million during the quarter, compared to analysts’ expectations of $6.20 million.

Zomedica Stock Down 18.3 %

Shares of ZOM opened at $0.19 on Friday. Zomedica has a 12 month low of $0.15 and a 12 month high of $0.41.

Wall Street Analyst Weigh In

Separately, Dawson James assumed coverage on Zomedica in a research report on Friday, January 6th. They set a “buy” rating and a $6.00 price target for the company.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of ZOM. Swiss National Bank increased its position in shares of Zomedica by 7.6% during the first quarter. Swiss National Bank now owns 2,201,200 shares of the company’s stock worth $742,000 after acquiring an additional 156,100 shares during the last quarter. BlackRock Inc. increased its position in shares of Zomedica by 5.6% during the first quarter. BlackRock Inc. now owns 13,418,299 shares of the company’s stock worth $4,523,000 after acquiring an additional 707,993 shares during the last quarter. West Michigan Advisors LLC purchased a new stake in shares of Zomedica during the first quarter worth about $28,000. UBS Group AG increased its position in shares of Zomedica by 207.6% during the first quarter. UBS Group AG now owns 200,000 shares of the company’s stock worth $67,000 after acquiring an additional 134,984 shares during the last quarter. Finally, Renaissance Technologies LLC purchased a new stake in shares of Zomedica during the second quarter worth about $552,000. Institutional investors and hedge funds own 9.42% of the company’s stock.

About Zomedica

(Get Rating)

Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company engages in the development and commercialization of TRUFORMA platform, which offers point-of-care diagnostic products for disease states in dogs and cats; and PulseVet, provides for treatment of various musculoskeletal issues, such as broken bones, tendonitis, and torn ligaments in horses and small animals.